Search clinical trials for: EMPAGLIFLOZIN PLACEBO

Total 54383 results

AstraZeneca

Completed

The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM

Type 1 Diabetes Mellitus

Japan
AstraZeneca
Bristol-Myers Squibb

Completed

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

Type 2 Diabetes Mellitus

Korea, Republic of, United States, Mexico, India, Puerto Rico, Russian Federation
Boehringer Ingelheim

Completed

4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)

Diabetes Mellitus, Type 2

Japan
Ann & Robert H Lurie Children's Hospital of Chicago
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Not yet recruiting

Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease (SGLT2I-IN-KIDS)

Chronic Kidney Diseases | Pediatric Kidney Disease

United States
University Health Network, Toronto

Not yet recruiting

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis (CANARY)

End Stage Kidney Disease | Kidney Dysfunction | Peritoneal Dialysis Complication | Sodium-glucose Co-transporter-2 Inhibitors | Residual Kidney Function

Canada
Chinese University of Hong Kong

Recruiting

Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction (EMPA)

Acute Heart Failure

Hong Kong
Boehringer Ingelheim

Recruiting

Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure

Heart Failure

Korea, Republic of
Assiut University

Completed

Effect of Sodium Glucose Cotransporter Inhibitors on Non Diabetic Fatty Liver Disease Patients (Fatty liver)

Fatty Liver Disease

Egypt
Mutah University

Completed

Pharmacokinetics and Bioequivalence of Two Empagliflozin, With Evaluation in Healthy Jordanian Subjects Under Fasting and Fed Conditions

Pharmacokinetic Parameters

Jordan
Medical University of Vienna

Completed

Empagliflozin in Post-Transplantation Diabetes Mellitus (EMPTRA-DM)

Posttransplant Diabetes Mellitus

Austria
Henrik Enghusen Poulsen
University of Copenhagen; University Hospital, Gentofte, Copenhagen

Completed

The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes (EMPOX)

Diabetes Mellitus, Type 2

Denmark
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

Diabetes Mellitus, Type 1

United States, Spain, Taiwan, Belgium, United Kingdom, Germany, Canada, Australia, Finland, Netherlands, Poland, France, Denmark, Norway, Sweden, Austria, Czechia
Boehringer Ingelheim
Eli Lilly and Company

Completed

Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Yooyoung Pharmaceutical Co., Ltd.

Active, not recruiting

Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients

Type 2 Diabetes

Korea, Republic of
Dong Wha Pharmaceutical Co. Ltd.

Completed

This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component(Empagliflozin and Metformin) in Healthy Adult Volunteers in Fast Condition.

Healthy Subjects

Korea, Republic of
Samuel Lunenfeld Research Institute, Mount Sinai...
McGill University Health Centre/Research Institute of the McGill University...

Completed

Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient Setting (CLASS17)

Type1 Diabetes Mellitus

Canada
AstraZeneca

Completed

Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants

Chronic Kidney Disease

United States
University Hospital, Gentofte, Copenhagen
Eli Lilly and Company

Completed

The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors

Type 2 Diabetes

Denmark
University Hospital Tuebingen
AstraZeneca; German Federal Ministry of Education and Research; German Center...

Recruiting

SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes

Renal Failure | PreDiabetes | Type2diabetes

Germany
Sheba Medical Center

Unknown

Effects of SGLT2 Inhibitor in Diabetic Patients With Coronary Artery Disease

Coronary Disease With Diabetes Mellitus

Israel
Rigshospitalet, Denmark

Recruiting

EMPagliflozin After Aortic Valve Replacement (EMPAVR)

Aortic Valve Stenosis

Denmark
Johannes Gutenberg University Mainz
Boehringer Ingelheim

Completed

Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics (EmDia)

Diabetes Mellitus, Type 2 | Diastolic Dysfunction

Germany
Unity Health Toronto
Boehringer Ingelheim

Unknown

Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes (EMPA-HEART)

Cardiovascular Disease | Diabetes

Canada
National Institute of Diabetes and Digestive and...

Withdrawn

Empaglifozin in Early Diabetic Kidney Disease

Diabetic Kidney Disease | Diabetes Mellitus Type 2

United States
University Hospital, Basel, Switzerland

Completed

Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study (SAND)

SIADH

Switzerland
Chinese PLA General Hospital

Unknown

Empagliflozin on Cardiac-renal Injury in Patients With STEAMI Patients After Primary PCI

Reperfusion Injury, Myocardial
AstraZeneca

Completed

The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions

Healthy Subjects in Fasted and Fed State

Brazil
University of Mississippi Medical Center
Eli Lilly and Company

Recruiting

Empagliflozin in ESKD - A Feasibility Study

Heart Failure | Kidney Failure, Chronic

United States
Boehringer Ingelheim
Eli Lilly and Company; Medical Research Council Population Health Research...

Active, not recruiting

EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

Chronic Kidney Disease

United States, Canada, United Kingdom, China, Germany, Italy, Japan, Malaysia
Oslo University Hospital

Completed

Empagliflozin in Renal Transplant Recipients (EMPA-RenalTx)

Diabetes Mellitus | Renal Insufficiency | Safety Issues

Norway
Boehringer Ingelheim

Completed

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

China
Alexandria University

Completed

Empagliflozin as a Novel Therapy in Refractory Ascites

Ascites Hepatic

Egypt
International Bio service

Not yet recruiting

Bioequivalence Study of Empagliflozin 25 mg Film-coated Tablets in Healthy Thai Volunteers

Healthy Volunteer
Fayoum University
Cairo University

Not yet recruiting

SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?

SGLT2i Kideny Protection Against Contrast in Diabetic Kidney
Humanis Saglık Anonim Sirketi

Completed

Bioequivalence Study of Empagliflozin 25 mg Film Coated Tablets of Humanis, Turkey and Jardiance (Empagliflozin) 25 mg Film-coated Tablets of Boehringer Ingelheim International GmbH, Germany in Normal, Healthy, Adult, Human Subjects Under Fasting Condition

Type2 Diabetes Mellitus

India
Shanghai Zhongshan Hospital

Active, not recruiting

Remission of Type 2 Diabetes With Dapagliflozin (READ Trial) (READ)

Type 2 Diabetes

China
Dong-A ST Co., Ltd.

Completed

Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Type 2 Diabetes

Korea, Republic of
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Pharma Nueva

Not yet recruiting

A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions

Healthy Vollunteer
Icahn School of Medicine at Mount Sinai
Eli Lilly and Company; Boehringer Ingelheim

Completed

Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4). (EMPA-TROPISM)

Cardiovascular Diseases

United States
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; McGill University; VA Boston Healthcare...

Active, not recruiting

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (CER-4-T2D)

Type2 Diabetes | Renal Disease | Cardiovascular Events

United States
University Health Network, Toronto

Recruiting

Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial (NATRIURETIC)

Type 2 Diabetes Mellitus

Canada
Yale University
Boehringer Ingelheim

Completed

Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects (EMPA)

Heart Failure | Type II; Diabetes

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus

Obesity | Diabetes Mellitus, Type 2

United States, Belgium, Bulgaria, Colombia, Czech Republic, Finland, France, Germany, Guatemala, Mexico, Peru, Russian Federation, Spain, Ukraine
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment

Diabetes Mellitus, Type 2 | Renal Insufficiency

United States, Canada, France, Hong Kong, India, Malaysia, Netherlands, Philippines, Poland, Portugal, Russian Federation, Slovakia, South Africa, Spain, United Kingdom
Matthew Neal MD
National Heart, Lung, and Blood Institute (NHLBI)

Active, not recruiting

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE (ACTIV-4A)

Covid19

United States, Spain, Brazil, Italy
University of California, San Diego
Juvenile Diabetes Research Foundation; The Leona M. and Harry B. Helmsley Charitable... and other collaborators

Completed

Combination GRA and SGLT-2i Treatment in Type 1 Diabetes

Type 1 Diabetes

United States
University of Sao Paulo General Hospital

Recruiting

SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI) (SAFE-PCI)

Coronary Artery Disease | Diabetes Mellitus, Type 2 | Acute Kidney Injury

Brazil
Yonsei University

Unknown

Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver

Type2 Diabetes | NAFLD - Nonalcoholic Fatty Liver Disease

Korea, Republic of

Search clinical trials for: EMPAGLIFLOZIN PLACEBO

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations